Vor Biopharma Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 26.26 million compared to USD 23.91 million a year ago. Basic loss per share from continuing operations was USD 0.39 compared to USD 0.53 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.69 USD | -0.59% | -1.17% | -24.89% |
Mar. 21 | Stifel Cuts Price Target on Vor Biopharma to $12 From $15, Maintains Buy Rating | MT |
Mar. 21 | Oppenheimer Cuts Vor Biopharma Price Target to $15 From $18, Maintains Outperform Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.89% | 115M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- VOR Stock
- News Vor Biopharma Inc.
- Vor Biopharma Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023